These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25382430)

  • 21. HDAC inhibitor-based therapies: can we interpret the code?
    New M; Olzscha H; La Thangue NB
    Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
    Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
    World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
    Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
    Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
    Schobert R; Biersack B
    Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.
    Kumar S; Attrish D; Srivastava A; Banerjee J; Tripathi M; Chandra PS; Dixit AB
    Expert Opin Ther Targets; 2021 Jan; 25(1):75-85. PubMed ID: 33275850
    [No Abstract]   [Full Text] [Related]  

  • 32. New and emerging HDAC inhibitors for cancer treatment.
    West AC; Johnstone RW
    J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylases as targets for multiple diseases.
    Sangshetti JN; Sakle NS; Dehghan MH; Shinde DB
    Mini Rev Med Chem; 2013 Jun; 13(7):1005-26. PubMed ID: 22876951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective histone deacetylase inhibitors.
    Pan H; Cao J; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):247-70. PubMed ID: 22263804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
    Luo Y; Li H
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.